No abstract

No abstract

Dysphagia lusoria is a condition in which hesitancy or difficulty in swallowing occurs because of pressure on the esophagus by an anomalous right subclavian artery. Bayfordl in 1794, described the symptoms produced by this anomaly and coined the term &dquo;dysphagia lusoria,&dquo; which meant difficulty in swallowing due to a quirk of nature. Kommerell2 described the roentgenologic findings in 1936. In these patients the right subclavian artery instead of arising in normal fashion from the innominate artery takes origin from the left side of the aortic arch so that the vessel must course upward and to the right, crossing the midline to reach its normal pathway. In 1946, Gross3 ligated and divided the anomalous subclavian artery in a child. Since that time this has become the standard corrective procedure for this condition. However, in elderly patients, division of this major vessel may result in impairment of blood flow to the corresponding arm.4 Weakness of the right hand and arm resulting from such an operation is particularly serious since most individuals are righthanded. Therefore, even though the collateral arterial supply of the upper extremity usually is adequate for survival following ligation or division of the anomalous subclavian artery, it would seem desirable to attempt to restore the continuity of this vessel. In light of the present state of development of vascular surgery, it would seem feasible enough to reestablish the continuity of this major source of blood to the right arm after division since anastomosis of an artery of this caliber poses almost no risk of thrombosis. TECHNIQUEThe establishment of continuity of the aberrant right subclavian artery consists of division nearly at its origin, suture closure of the stump on the aorta,

PAGE 33201:The curcumin nanoparticle binding assay described failed to indicate that 1 ml of chitosan (5 mg/ml stock at pH 5) was combined with PEG, curcumin, and phosphate-buffered saline in the first step and that hydrolyzed tetramethylorthosilicate (TMOS) was used, not trimethoxysilane. This protocol was based on the platform developed by Friedman et al. (Friedman, A. J., Han, G., Navati, M. S., Chacko, M., Gunther, L., Alfieri, A., and Friedman, J. M. (2008) Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 19,[12][13][14][15][16][17][18][19][20].